Half of all FDA-approved drugs in the past decade passed through Catalent. CEO Alessandro Maselli on growth, the culture and AI driving what’s next.

Catalent, a global leader in contract development and manufacturing (CDMO) for the biopharmaceutical industry, has played a role in approximately half of all FDA-approved drugs over the past decade, supporting over 1,000 active development programs, nearly 7,000 products, and 60 billion+ doses produced annually across nearly 40 sites worldwide.

In this interview with The CEO Magazine, Alessandro Maselli, President and CEO, explains how a business whose roots stretch back to R.P. Scherer’s invention of the softgel capsule in 1933, and which became Catalent following its 2007 separation from Cardinal Health, has evolved after nearly two decades of strategic investment and expansion into one of the few global CDMOs offering true end-to-end capabilities across oral technologies, biologics, cell and gene therapy and advanced modalities.

Maselli discusses Catalent’s “follow the molecule” philosophy, its “Patient First” culture, its strategic partnerships and how the company is investing heavily in AI to accelerate drug development, improve affordability and support an AI-augmented workforce.

Read the full interview: https://digitalmag.theceomagazine.com/alessandro-maselli/?r=global